Arcellx Continued Robust Long-Term Responses from Its CART-ddBCMA Phase 1 in Myeloma

 Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months –

-- The estimated median progression free survival by Kaplan-Meier is 28 months --

-- Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT --

-- Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m. --

Arcellx will host a live webcast event with an expert panel of clinicians to discuss the clinical results on Monday, December 11, 2023 at 8 p.m. PT. The event will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.

https://www.biospace.com/article/releases/arcellx-announces-continued-robust-long-term-responses-from-its-cart-ddbcma-anito-cel-phase-1-expansion-trial-in-patients-with-relapsed-or-refractory-multiple-myeloma-at-ash/